Lovastatin

  • 2beta, 6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone
  • 1,2,6,7,8,8a-Hexahydro-beta,delta-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutyoxy)-1-naphthaleneheptanoic acid delta-lactone
  • (1s,3r,7s,8s,8ar)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl(S)-2-methyl- butyrate
Formula
C24H36O5
Structure
Description
White crystals.
Uses
Medication.

Registry Numbers and Inventories.
CAS
75330-75-5
RTECS
EK7907000
RTECS class
Drug; Reproductive Effector; Human Data
Merck
12,5616
Beilstein/Gmelin
3631989
New Zealand
Listed

Properties.
Formula
C24H36O5
Formula mass
404.55
Melting point, °C
174.5 (under nitrogen)
Solubility in water
insoluble

Hazards and Protection.
Storage
Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage.
Handling
All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.
Protection
Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots.
Respirators
Use NIOSH/MSHA approved respirator appropriate for exposure of concern.
Small spills/leaks
Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces.
Stability
No data.
Incompatibilities
Strong oxidizing agents.

Fire.
Fire fighting
Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire.

Health.
Exposure effects
peripheral neuropathies have been reported following therapy with the hmg-coa enzyme inhibitors. Therapeutic administration of hmg-coa enzyme inhibitors may cause insomnia, behavioral changes, and extrapyramidal symptoms. Congenital abnormalities were reported in an infant whose mother ingested dextroamphetamine and lovastatin during the first trimester. <br>Skeletal abnormalities of the ribs and vertebra have been reported in female rats administered lovastatin 800 mg/kg/day during gestation. <br>Animal studies indicate HMG-CoA enzyme inhibitors are excreted into breast milk.
   Ingestion
Diarrhea and flatulence were commonly reported adverse effects during clinical trials. Pancreatitis was associated with gemfibrozil-lovastatin combined therapy.
   Skin
Dermatitis, photosensitivity, and dermatomyositis may occur following therapy with hmg-coa reductase inhibitors.

First aid
 
   Ingestion
Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended.
   Inhalation
If symptoms develop, move individual away from exposure and into fresh air. If symptoms persist, seek medical attention. If breathing is difficult, administer oxygen. Keep person warm and quiet; seek immediate medical attention.
   Skin
Remove contaminated clothing. Wash exposed area with soap and water. If symptoms persist, seek medical attention. Launder clothing before reuse.
   Eyes
If symptoms develop, immediately move individual away from exposure and into fresh air. Flush eyes gently with water for at least 15 minutes while holding eyelids apart; seek immediate medical attention.

Transport.